Please assess the completion status of the following clinical trial:

Trial Title: MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is at high cardiovascular risk and meets one of the following conditions: has never taken lipid-lowering therapy or has been off such therapy for at least 6 weeks; or, is currently taking a stable dose of certain lipid-lowering agents~* Patient is willing to maintain a cholesterol lowering diet during the study~* Female patients receiving non-cyclical hormone therapy have maintained a stable dose and regimen for at least 8 weeks and are willing to continue the same regimen during the study~Exclusion Criteria:~* Patient is Asian~* Patient routinely has more than 2 alcoholic drinks per day~* Female patient is pregnant or breastfeeding~* Patient has congestive heart failure~* Patient has had a myocardial infarction, coronary bypass surgery, angioplasty, or acute coronary syndrome within 3 months of screening~* Patient has uncontrolled cardiac arrhythmias~* Patient has had a partial ileal or gastric bypass or other significant intestinal malabsorption~* Patient has uncontrolled high blood pressure~* Patient has kidney disease~* Patient has any disease known to influence blood lipid levels~* Patient has any disorders of the blood, digestive system, or nervous system including stroke and degenerative disease that would limit study participation~* Patient has poorly controlled or newly diagnosed diabetes~* Patient is known to be HIV positive~* Patient has a history of cancer in the last 5 years, except certain skin and cervical cancers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Phase I: ezetimibe (EZ) 10 mg + atorvastatin (Atorva) 10 mg (Type: EXPERIMENTAL): Co-administration of EZ 10 mg tablet + Atorva 10 mg tablet; once daily for 6 weeks
- Phase I: Atorvastatin 20 mg (Type: ACTIVE_COMPARATOR): Atorvastatin 20 mg tablet once daily for 6 weeks
- Phase I: Rosuvastatin 10 mg (Type: ACTIVE_COMPARATOR): Rosuvastatin 10 mg tablet once daily for 6 weeks
- Phase II: EZ 10mg+Atorva 10mg (Type: EXPERIMENTAL): Participants who had previously received EZ 10 mg + Atorva 10 mg in Phase I and continued on EZ 10 mg + Atorva 10 mg once daily for 6 weeks during Phase II regardless of whether or not LDL-C goals were achieved in Phase I
- Phase II: EZ 10mg + Atorva 20mg [A] (Type: EXPERIMENTAL): Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched to EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II
- Phase II: Atorva 40mg (Type: ACTIVE_COMPARATOR): Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched Atorva 40 mg once daily for 6 weeks in Phase II
- Phase II: EZ 10mg + Atorva 20mg [R] (Type: EXPERIMENTAL): Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and received EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II
- Phase II: Rosuvastatin 20mg (Type: ACTIVE_COMPARATOR): Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and were switched to Rosuvastatin 20 mg once daily for 6 weeks in Phase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete